OBJECTIVE: To assess CD4 T-cell responsiveness to IL-7 and IFN-α in HIV-infected patients who experience poor recovery of CD4 T-cell counts during therapy (immune failure patients). DESIGN: Responses to IL-7 and IFN-α were compared between HIV-infected immune failure (CD4 cell counts <379 cells/μl) patients and immune success (CD4 cell counts >500 cells/μl) as well as healthy control patients. METHODS: Flow cytometry was used to assess peripheral blood mononuclear cells for IL-7-induced proliferation, CD25 expression, and signaling (signal transducer and activator of transcription 5 phosphorylation and Akt phosphorylation) in CD4 T cells. Freshly isolated cells were characterized by expression of IL-7Rα (CD127) among CD4 T-cell maturation subsets by flow cytometry and sorted CD3 T cells were assessed for expression of IFN-α and interferon stimulated genes (2'-5'-oligoadenylate synthetase-1 and myxovirus resistance A protein) by quantitative real-time PCR. Responses to IFN-α were assessed by induction of signal transducer and activator of transcription 1 phosphorylation and inhibition of IL-7-induced CD4 T-cell proliferation. RESULTS: IL-7-induced proliferation and CD25 expression were decreased in CD4 T cells from immune failure patients. CD127 expressing CD4 T cells were decreased, whereas expression of 2'-5'-oligoadenylate synthetase-1, myxovirus resistance A protein, and IFN-α mRNA were increased in total CD3 T cells from immune failure patients. CD127 expression correlated with CD25 induction but not proliferation, whereas T-cell IFN-α mRNA was associated with reduced proliferation in CD4 T cells from immune failure patients. IFN-α-mediated induction of signal transducer and activator of transcription 1 phosphorylation and inhibition of proliferation were not diminished in CD4 T cells from immune failure patients. CONCLUSION: IL-7 responsiveness is impaired in immune failure patients and may be related to expression of CD127 and IFN-α.
OBJECTIVE: To assess CD4 T-cell responsiveness to IL-7 and IFN-α in HIV-infectedpatients who experience poor recovery of CD4 T-cell counts during therapy (immune failurepatients). DESIGN: Responses to IL-7 and IFN-α were compared between HIV-infected immune failure (CD4 cell counts <379 cells/μl) patients and immune success (CD4 cell counts >500 cells/μl) as well as healthy control patients. METHODS: Flow cytometry was used to assess peripheral blood mononuclear cells for IL-7-induced proliferation, CD25 expression, and signaling (signal transducer and activator of transcription 5 phosphorylation and Akt phosphorylation) in CD4 T cells. Freshly isolated cells were characterized by expression of IL-7Rα (CD127) among CD4 T-cell maturation subsets by flow cytometry and sorted CD3 T cells were assessed for expression of IFN-α and interferon stimulated genes (2'-5'-oligoadenylate synthetase-1 and myxovirus resistance A protein) by quantitative real-time PCR. Responses to IFN-α were assessed by induction of signal transducer and activator of transcription 1 phosphorylation and inhibition of IL-7-induced CD4 T-cell proliferation. RESULTS:IL-7-induced proliferation and CD25 expression were decreased in CD4 T cells from immune failurepatients. CD127 expressing CD4 T cells were decreased, whereas expression of 2'-5'-oligoadenylate synthetase-1, myxovirus resistance A protein, and IFN-α mRNA were increased in total CD3 T cells from immune failurepatients. CD127 expression correlated with CD25 induction but not proliferation, whereas T-cell IFN-α mRNA was associated with reduced proliferation in CD4 T cells from immune failurepatients. IFN-α-mediated induction of signal transducer and activator of transcription 1 phosphorylation and inhibition of proliferation were not diminished in CD4 T cells from immune failurepatients. CONCLUSION:IL-7 responsiveness is impaired in immune failurepatients and may be related to expression of CD127 and IFN-α.
Authors: Michael M Lederman; Leonard Calabrese; Nicholas T Funderburg; Brian Clagett; Kathy Medvik; Hector Bonilla; Barbara Gripshover; Robert A Salata; Alan Taege; Michelle Lisgaris; Grace A McComsey; Elizabeth Kirchner; Jane Baum; Carey Shive; Robert Asaad; Robert C Kalayjian; Scott F Sieg; Benigno Rodriguez Journal: J Infect Dis Date: 2011-10-15 Impact factor: 5.226
Authors: K A Lichtenstein; D J Ward; A C Moorman; K M Delaney; B Young; F J Palella; P H Rhodes; K C Wood; S D Holmberg Journal: AIDS Date: 2001-07-27 Impact factor: 4.177
Authors: Joseph A Fraietta; Yvonne M Mueller; Guibin Yang; Alina C Boesteanu; Donald T Gracias; Duc H Do; Jennifer L Hope; Noshin Kathuria; Shannon E McGettigan; Mark G Lewis; Luis D Giavedoni; Jeffrey M Jacobson; Peter D Katsikis Journal: PLoS Pathog Date: 2013-10-10 Impact factor: 6.823
Authors: Joseph E Henriquez; Michael D Rizzo; Robert B Crawford; Peter Gulick; Norbert E Kaminski Journal: J Pharmacol Exp Ther Date: 2018-07-19 Impact factor: 4.030
Authors: Sho Sugawara; Ramy El-Diwany; Laura K Cohen; Kimberly E Rousseau; Christopher Y K Williams; Rebecca T Veenhuis; Shruti H Mehta; Joel N Blankson; David L Thomas; Andrea L Cox; Ashwin Balagopal Journal: J Virol Date: 2021-03-03 Impact factor: 5.103
Authors: Souheil-Antoine Younes; Aarthi Talla; Susan Pereira Ribeiro; Evgeniya V Saidakova; Larisa B Korolevskaya; Konstantin V Shmagel; Carey L Shive; Michael L Freeman; Soumya Panigrahi; Sophia Zweig; Robert Balderas; Leonid Margolis; Daniel C Douek; Donald D Anthony; Pushpa Pandiyan; Mark Cameron; Scott F Sieg; Leonard H Calabrese; Benigno Rodriguez; Michael M Lederman Journal: J Clin Invest Date: 2018-10-15 Impact factor: 19.456
Authors: Julia Roider; Abigail Ngoepe; Maximilian Muenchhoff; Emily Adland; Andreas Groll; Thumbi Ndung'u; Henrik Kløverpris; Philip Goulder; Alasdair Leslie Journal: Front Immunol Date: 2019-02-12 Impact factor: 7.561